Table 2:

Number, proportion (with 95% confidence intervals [CI]), and crude risk ratios (with 95% CIs) showing the association of adjunctive azithromycin versus placebo with the risk of infectious maternal morbidity among patients undergoing unscheduled cesarean deliveries by time of administration of study drug

Outcomes	After skin incision (Median 3 mins, range 0-229mins) N=269		0-30mins pre-incision N=1378		>30-60mins pre-incision N=270		>60mins pre-incision (Median 85mins, range 61-218 mins) N= 96		Interaction p-value
	Azithromycin n=135	Placebo (ref) * n=134	Azithromycin n=693	Placebo (ref) * n=685	Azithromycin n=140	Placebo (ref) * n=130	Azithromycin n=51	Placebo (ref) * n=45
Primary composite outcome N=181	6 (4.4) [1.8-10.3]	19 (14.2) [8.7-22.2]	46 (6.6) [4.8-9.1]	73 (10.7) [8.3-13.6]	8 (5.7) [2.7-11.8]	24 (18.5) [12.6-27.2]	2 (3.9) [0.9-15.2]	3 (6.7) [0.2-20.0]	0.18
	0.31 (0.13-0.76)		0.62 (0.44-0.89)		0.31 (0.13-0.66)		0.59 (0.10-3.36)
Endometritis N=100	2 (1.5) [0.3-6.1]	12 (9.0) [4.8-16.1]	32 (4.6) [3.1-6.8]	34 (5.0) [3.4-7.2]	5 (3.6) [1.4-9.0]	13 (10.0) [5.5-17.5]	0 (0.0) [0.0-9.0]	2 (4.4) [1.0-17.0]	0.22
	0.16 (0.04-0.73)		0.93 (0.58-1.49)		0.36 (0.13-0.97)		†
Wound infection N=90	4 (3.0) [1.0-8.3]	10 (7.5) [3.8-14.2]	15 (2.2) [1.2-3.8]	42 (6.1) [4.4-8.2]	3 (2.1) [0.6-7.0]	12 (9.2) [5.0-16.5]	2 (3.9) [0.9-15.2]	2 (4.4) [1.0-17.0]	0.68
	0.40 (0.13-1.23)		0.35 (0.20-0.63)		0.23 (0.07-0.80)		0.88 (0.13-6.01)

^*(ref)- Reference group

^†Regression model did not converge due to small case numbers

^‡Results for other infections were excluded from table due to non-convergence of models from small case numbers

^§Numbers in brackets are 95% confidence intervals for the proportions